Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) vs Turkmenistan: Immunization, Hib3
Immunization, Hib3 over time
- Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
- Turkmenistan
How they compare
Turkmenistan currently reports 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), a difference of 14.3%.
That makes Turkmenistan's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)'s.
Across all 15 years both countries report, Turkmenistan has been ahead every year.
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 21st and Turkmenistan ranks 20th of 43 groups.
Turkmenistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) | Turkmenistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 67.9% | 91.4% | 23.5% | Turkmenistan |
| 2020s | 82.5% | 98.0% | 15.5% | Turkmenistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) or Turkmenistan?
- Turkmenistan, at 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) as of 2024.
- What is the difference in immunization, hib3 between Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) and Turkmenistan?
- 14.3%, with Turkmenistan ahead.
- How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) and Turkmenistan?
- 15 years are reported by both, from 2010 to 2024.
- How do Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) and Turkmenistan rank globally for immunization, hib3?
- Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 21st and Turkmenistan ranks 20th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.